Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Subjects With Advanced Primary Liver Cancer

NCT05411757 is registered in ClinicalTrials.gov with Shandong Public Health Clinical Center as lead sponsor.

NCT NCT05411757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Subjects With Advanced Primary Liver Cancer
Lead sponsor
Shandong Public Health Clinical Center
Phase
Phase 1
Overall status
Unknown status
Start date
June 30, 2022
Completion date
December 30, 2023
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced primary liver cancer